ERBB2 and breast cancer: To the best of our knowledge, the present study provides a first evidence of the involvement of HER2/β-catenin signaling as a potential target in paclitaxel-resistant breast cancer, along with the observation that PFL was able to inhibit the expression of HER2, β-catenin and its downstream molecules in paclitaxel-sensitive and resistant cells.